- RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
This study looks at a new medicine called alectinib for children and teenagers with specific cancers that haven't responded to other treatments. Doctors want to see if it's safe, how it works in the body, and if it can help treat these cancers.
For: ALK Fusion-positive Solid or CNS TumorsUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study looks at new treatments for a type of lung cancer that hasn't spread widely but can't be removed by surgery. It aims to see how well these medicines work and if they are safe after standard initial treatments.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
The DETERMINE trial is testing if existing cancer medicines can help people with rare cancers or common cancers with rare genetic changes. It includes adults, teenagers, and children. The goal is to find new ways to treat cancer and make these treatments available through the NHS.
For: Haematological Malignancy · Solid TumourUnited Kingdom - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
For: Non-small Cell Lung Cancer · Anaplastic Lymphoma Kinase-positiveUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - AuthorisedTherapeutic exploratory (Phase II)
Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020
This study is looking at a new medicine called ALECTINIB for people with a certain type of lung cancer (ALK+ Stage III NSCLC). We want to see how well it shrinks tumours before an operation and if it's safe to use. It's a Phase II study, meaning we're exploring its effects.
For: Patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small · Cell Lung Cancer (NSCLC)Italy - Active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.
For: Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative DisordersUnited Kingdom - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
For: CancerUnited States · Australia · Belgium